Advertisement

Topics

CTI BioPharma Announces Completion Of Enrollment In The Phase III PIX306 Trial Of PIXUVRI For Aggressive B-Cell Non-Hodgkin Lymphoma

20:00 EDT 1 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: CTI BioPharma Announces Completion Of Enrollment In The Phase III PIX306 Trial Of PIXUVRI For Aggressive B-Cell Non-Hodgkin Lymphoma

NEXT ARTICLE

More From BioPortfolio on "CTI BioPharma Announces Completion Of Enrollment In The Phase III PIX306 Trial Of PIXUVRI For Aggressive B-Cell Non-Hodgkin Lymphoma"

Quick Search
Advertisement